• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Grace Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    6/23/25 8:00:43 AM ET
    $GRCE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRCE alert in real time by email
    false0001444192DECommon Stock, par valueNASDAQ00014441922025-06-232025-06-23

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549


    FORM 8-K


    CURRENT REPORT
     
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): June 23, 2025

    GRACE THERAPEUTICS, INC.
    (Exact name of Registrant as Specified in Its Charter)


    State of Delaware
    001-35776
    98-1359336
    (State or Other Jurisdiction of Incorporation)
    (Commission File Number)
    (IRS Employer Identification No.)

    103 Carnegie Center
    Suite 300
       
    Princeton, New Jersey
     
    08540
    (Address of Principal Executive Offices)
     
    (Zip Code)

    Registrant’s Telephone Number, Including Area Code: 609-322-1602

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     
    Title of each class
     
    Trading
    Symbol(s)
     
     
    Name of each exchange on which registered
    Common Stock, par value $0.0001 per share
     
    GRCE
     
    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 2.02
    Results of Operations and Financial Condition.

    The following information is furnished pursuant to Item 2.02 “Results of Operations and Financial Condition.”

    On June 23, 2025, Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.) issued a press release announcing its financial results for the fiscal year ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

    The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing or document.

    Item 9.01
    Exhibits.
     
    (d) Exhibits

    Exhibit
     
    Description
    99.1
     
    Press Release, dated June 23, 2025.
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

         
    GRACE THERAPEUTICS, INC.
           
    Date:
    June 23, 2025
    By:
    /s/ Prashant Kohli
         
    Prashant Kohli
         
    Chief Executive Officer



    Get the next $GRCE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRCE

    DatePrice TargetRatingAnalyst
    5/2/2025$12.00Buy
    TD Cowen
    More analyst ratings

    $GRCE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Grace Therapeutics with a new price target

      TD Cowen initiated coverage of Grace Therapeutics with a rating of Buy and set a new price target of $12.00

      5/2/25 8:14:37 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRCE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update

      Held Type C meeting with FDA on Planned New Drug Application (NDA) Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control (CMC) Requirements NDA On Track for Submission to FDA in First Half of Calendar 2025 NDA to be Supported by Data from Phase 3 STRIVE-ON Safety Trial, which Met Primary Endpoint and Provided Evidence of Clinical Benefit Compared to Orally Administered Nimodipine Secured Private Placement Financing of $15 Million in Upfront Gross Proceeds with the Potential to Receive up to an Additional $15 Million in Potential Warrant Exercise Proceeds for an Aggregate of Up to Approximately $30 Million in Potential Total Gross Proceeds PRINCETON, N.J.

      6/23/25 8:00:00 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grace Therapeutics to Participate in the 2025 BIO International Conference

      PRINCETON, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate in the upcoming BIO 2025 International Conference, to be held in Boston, MA, June 16-19, 2025. Hosted by the Biotechnology Innovation Organization (BIO), the BIO International Convention is the world's largest and most influential biotechnology event

      6/13/25 8:00:00 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104

      PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced details of the Company's Type C meeting with the U.S. Food and Drug Administration (FDA). The purpose of this meeting was to obtain FDA feedback on the completed Phase 3 STRIVE-ON safety trial of GTx-104 and its planned New Drug Application (NDA) submission including clinical, non-clinical, and chemistry, manu

      4/9/25 8:00:00 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRCE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Kottayil George

      4 - Grace Therapeutics, Inc. (0001444192) (Issuer)

      5/13/25 5:21:16 PM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Davis A Brian

      4 - Grace Therapeutics, Inc. (0001444192) (Issuer)

      5/13/25 5:21:13 PM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kavuru Vimal

      4 - Grace Therapeutics, Inc. (0001444192) (Issuer)

      5/13/25 5:21:11 PM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRCE
    SEC Filings

    See more
    • Grace Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Grace Therapeutics, Inc. (0001444192) (Filer)

      6/23/25 8:00:43 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Grace Therapeutics Inc.

      10-K - Grace Therapeutics, Inc. (0001444192) (Filer)

      6/23/25 7:43:32 AM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Grace Therapeutics Inc.

      SCHEDULE 13G - Grace Therapeutics, Inc. (0001444192) (Subject)

      5/15/25 4:46:05 PM ET
      $GRCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRCE
    Leadership Updates

    Live Leadership Updates

    See more
    • Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

      BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu

      3/11/25 7:00:00 AM ET
      $GRCE
      $MTNB
      $ONVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)